Cell: Significant progress! Chinese scientists discover 14 human antibodies that can be powerful lyint and SARS-CoV-2

2020 May 19 News /BioValleyBIOON / --- In a new study, from Peking University, Capital Medical University, Military Medical Sciences, Chinese Academy of Medical Sciences Dan sequence and researchers Beijing Pharmaceutical Co., Ltdis a high-throughput single cell sequencing, successfully identified for a variety of novel coronavirus SARS-CoV-2 --- cause respiratory disease caused by COVID-19 from the convalescent plasma high-strength effect of neutralizing antibodies --- the virusNeutralizing antibodies produced by the body's immune system can effectively prevent the virus from infected cellsNew results from animal studies have shown that these neutralizing antibodies they found provide a potential therapeutic approach, as well as short-term means for the prevention COVID-19This marks an important milestone in resistance COVID-19 epidemicresearch results in 2020, published online May 17 in the journal Cell, the paper titled "PotentneutralizingantibodiesagainstSARS-CoV-2identifiedbyhigh-throughputsingle-cellsequencingofconvalescentpatients'Bcells"Corresponding author for the paper Peking University, Beijing University, Beijing You An Hospital, vice president future gold director Genesophisticated diagnosticInnovation Center Xiaoliang Sunney Xie, director of the Institute of Experimental Animals Chinese Academy of Medical Sciences Qin Chuan, Capital Medical University Winner and Academy of military Medical Microbiology and Epidemiology Institute of Virology director Qincheng Fengimages from Cell, 2020, doi: 10.1016 / j.cell.2020.05.025It has long been an urgent need for effective drugs to cure COVID-19Re-use of small molecule drugs lack specificity, and therefore efficacy is affectedAlthough plasma treatment showed some effect, but the supply is limited convalescent plasmaPlasma treatment is an effective ingredient in targeting antibodiesAntibody drug as a biological agent has been successfully used to treat HIV, Ebola, MERS-CoV coronavirus and other viruses However, to develop neutralizing antibodies suitable for clinical use, often it takes months or even years use in single-cell genomics 's expertise, Beijing gene future sophisticated diagnostic Innovation Center of Peking University Xiaoliang Sunney Xie team with the Capital Medical University, Beijing Medical researchers YouAn cooperation vice president, blood samples were collected from convalescent patient more than 60, in which blood samples were screened out from 14 kinds of high-strength efficiency of the 8558 antigen binding IgG1 + clonotypes (clonotype) in and antibodies As their most potent antibody, BD-368-2 IC of SARS-CoV-2 virus false and true SARS-CoV-2 viruses was respectively 50 8pM and 100pM For real experimental SARS-CoV-2 virus is completed in the Military Medical Academy P3 laboratory These researchers used the Institute of Experimental Animals Chinese Academy of Medical Sciences, Dr Qin Chuan developed in the laboratory hACE2 transgenic mouse model, completed the experiment in vivo anti-virus neutralizing antibodies The results show, BD-368-2 antibody has a strong preventive effect and a therapeutic effect on the SARS-CoV-2: the BD-368-2 antibodies when injected into the body of mice infected, viral load decreased by approximately 2400 times; BD-368-2 antibodies when injected into mice uninfected them from infection Furthermore, structural biologists Peking XiaodongSu, JunyuXiao group members and also received neutralizing antibodies BD-23 and spike protein - complex extracellular domain trimers are formed at a low temperature of 3.8 Å resolution electron microscopy structure The results showed that the epitope binding site of an antibody to ACE2 coincide, which provides the structural basis for the antibody and neutralization In addition, they found that, based on the SARS-CoV-2 neutralizing antibody structure prediction and SARS-CoV neutralizing antibodies are similar, one can efficiently screening SARS-CoV-2 neutralizing antibodies, thus greatly speeding up the screening process these high strength efficiency and antibodies may be used in developing therapeutic intervention and prevention of drug in the SARS-CoV-2 Currently, ongoing clinical trials, Xiaoliang Sunney Xie team has a strong confidence in finding a cure Dr Xiaoliang Sunney Xie said, "If the epidemic COVID-19 again in the winter, then we find that the use of neutralizing antibodies develop drugs are likely to come out at that time." (Bio Valley Bioon.com) references: 1.YunlongCaoetal PotentneutralizingantibodiesagainstSARS-CoV-2identifiedbyhigh-throughputsingle-cellsequencingofconvalescentpatients'Bcells .Cell, 2020, doi:. 10.1016 / j.cell.2020.05.025
2.TeamfindseffectiveSARS-CoV-2neutralizingantibodies

https://phys.org/news/2020-05-team-effective-sars-cov-neutralizing-antibodies.html